Formycon First Half 2024 Earnings: €0.58 loss per share (vs €0.11 profit in 1H 2023)

Formycon (ETR:FYB) First Half 2024 Results

Key Financial Results

• Revenue: €26.9m (down 39% from 1H 2023).
• Net loss: €10.1m (down from €1.80m profit in 1H 2023).
• €0.58 loss per share (down from €0.11 profit in 1H 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Formycon Earnings Insights

Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.

Performance of the market in Germany.

The company's share price is broadly unchanged from a week ago.

Valuation

Our analysis of these results suggests Formycon may be undervalued based on 6 important criteria we look at. To explore our complete evaluation click here and get an understanding of what analysts are thinking about the company's future.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.